CITIUS ONCOLOGY, INC. - 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Citius Oncology, Inc. (Nasdaq: CTOR) on February 6, 2025. The company is an emerging growth company incorporated in Delaware. The report addresses a specific corporate event regarding its product, LYMPHIR (denileukin diftitox-cxdl).
Key Financial Metrics
This filing is a Current Report (Item 8.01) and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
The material event reported is the assignment of a unique, permanent Healthcare Common Procedure Coding System (HCPCS) J-code to LYMPHIR by the Centers for Medicare & Medicaid Services (CMS). This coding is essential for billing and reimbursement purposes for the drug.
Guidance, Outlook, and Risks
The filing incorporates a press release (Exhibit 99.1) announcing the J-code assignment. No specific financial guidance, forward-looking outlook, risk factors, or contingencies are detailed within the text of this specific 8-K form.
Investor Verification Checklist
- Verify the specific J-code assigned to LYMPHIR in the attached press release (Exhibit 99.1).
- Confirm the effective date for billing using the new J-code.
- Review the company's latest 10-K or 10-Q for current financial health and cash runway, as this 8-K contains no financial data.
- Monitor subsequent filings for updates on commercialization progress following the J-code assignment.